Healthcare investors are often faced with a choice between companies that generate steady growth across diversified businesses and those positioned to benefit from improving industry conditions. Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) represent those two approaches. Abbott (NYSE:ABT) continues to deliver broad-based growth across diagnostics, medical devices, and nutrition, while Thermo Fisher (NYSE:TMO) is showing early signs that the life sciences downturn may finally be easing.
Both companies reported encouraging results, but the question for investors is whether consistent execution or a cyclical recovery offers the stronger long-term opportunity.
Bull Case
Abbott’s (NYSE:ABT) strongest growth driver this quarter came from diagnostics, reinforcing the company’s ability to generate meaningful growth across multiple business segments. The company’s cancer diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard.
The quarter’s earnings report corroborates this, as sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter. The continued strength in diagnostics is particularly important because it adds another major growth engine alongside Abbott’s (NYSE:ABT) medical device business, making the company’s earnings profile more balanced.
While Abbott’s (NYSE:ABT) investment case is built on factors like diversification, Thermo Fisher’s (NYSE:TMO) outlook increasingly depends on improving conditions across the life sciences industry. The company’s quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Management highlighted improving customer activity across pharmaceutical and biotechnology markets, while multiple operating segments returned to healthy growth. That is an important distinction because broader participation across business segments suggests customer spending is becoming healthier rather than merely stabilizing in one niche.
Perhaps the biggest positive from the quarter was the recovery in Analytical Instruments, a business that had faced weak demand for nearly two years as biotechnology funding slowed. Its return to growth provides another indication that laboratory spending is beginning to normalize. Continued improvement in this business would provide one of the clearest signs that laboratory spending has moved beyond its post-pandemic correction.
Bear Case
Abbott (NYSE:ABT) has expressed confidence that sales and earnings growth will accelerate in the second half of 2026. While this outlook is supported by improving momentum across multiple business segments, investors will need to see that acceleration materialize over the coming quarters. Notably, Abbott Laboratories (NYSE:ABT) reaffirmed rather than raised its full-year comparable sales growth guidance of 6.5% to 7.5%, suggesting that management remains prudent despite its strong second-quarter performance.
In addition, Nutrition remains one of the few businesses still working through a slower recovery. Although sequential improvement is encouraging, investors will likely want to see that momentum continue before concluding the segment has returned to sustainable growth.
In Thermo Fisher’s (NYSE:TMO) case, one of the biggest risks is that investors extrapolate one strong quarter into a full industry recovery. Organic revenue increased 5%, representing meaningful progress but still remaining below the double-digit growth rates the company previously achieved. As a result, expectations for a rapid return to historic growth may prove optimistic. The company’s recovery also remains heavily dependent on pharmaceutical and biotechnology spending. If customers once again delay capital investment, today’s improving demand environment could prove less durable than the market currently expects.
Thermo Fisher’s (NYSE:TMO) guidance increase also raises the bar for future execution. As expectations improve, the company will likely need to demonstrate that the recovery in customer spending is sustainable rather than simply benefiting from a strong quarter.
Which Growth Story Looks More Durable?
Abbott (NYSE:ABT) and Thermo Fisher (NYSE:TMO) are growing for different reasons. Abbott’s (NYSE:ABT) results reflect the strength of a diversified healthcare business capable of generating growth across multiple segments. Thermo Fisher’s (NYSE:TMO) outlook, by contrast, depends more heavily on improving pharmaceutical and biotechnology spending following several challenging years. If the recovery in life sciences continues gathering momentum, Thermo Fisher (NYSE:TMO) could offer greater cyclical upside. However, Abbott’s (NYSE:ABT) broader portfolio may provide greater resilience if industry conditions weaken again.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
Disclosure: None. This article is originally published at Insider Monkey.
